BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11426466)

  • 21. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells.
    Vera M; Razquin N; Prieto J; Melero I; Fortes P; González-Aseguinolaza G
    Mol Ther; 2005 Nov; 12(5):950-9. PubMed ID: 15921960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
    Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT
    J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy.
    Lieu FH; Hawley TS; Fong AZ; Hawley RG
    Cancer Gene Ther; 1997; 4(3):167-75. PubMed ID: 9171935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
    Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Robinson BW; Scott B
    Am J Respir Cell Mol Biol; 1999 Sep; 21(3):347-56. PubMed ID: 10460752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy.
    Heinzerling L; Burg G; Dummer R; Maier T; Oberholzer PA; Schultz J; Elzaouk L; Pavlovic J; Moelling K
    Hum Gene Ther; 2005 Jan; 16(1):35-48. PubMed ID: 15703487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
    Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
    Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
    Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
    Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18.
    Nagai H; Hara I; Horikawa T; Fujii M; Kurimoto M; Kamidono S; Ichihashi M
    Cancer Invest; 2000; 18(3):206-13. PubMed ID: 10754989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
    Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
    Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
    van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
    Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
    Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
    Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
    Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
    Daud AI; DeConti RC; Andrews S; Urbas P; Riker AI; Sondak VK; Munster PN; Sullivan DM; Ugen KE; Messina JL; Heller R
    J Clin Oncol; 2008 Dec; 26(36):5896-903. PubMed ID: 19029422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
    Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
    Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.